CYP19A1 and breast carcinoma: With promising data from the Breast cancer trials of OraL EveROlimus-2 (BOLERO-2) trial, everolimus has been approved for use in combination with an aromatase inhibitor in post-menopausal patients with hormone receptor-positive metastatic breast cancer that have progressed on or after a non-steroidal aromatase inhibitor [52].